The only viable path for AI regulation is to treat it as a dual-use technology, similar to nuclear energy. Governments must clearly delineate and control 'weapons-grade' AI while fostering innovation in 'civilian use' AI. A failure to do so risks either falling behind in a global arms race or allowing dangerous capabilities to proliferate.

The debate pitting AI safety against AI opportunity presents a false choice. Historical parallels, like the railroad industry, show that safety regulations (e.g., standardized tracks, air brakes) were essential for enabling greater speed, reliability, and economic potential. Trustworthy AI will unlock greater opportunity.

When addressing AI's 'black box' problem, lawmaker Alex Boris suggests regulators should bypass the philosophical debate over a model's 'intent.' The focus should be on its observable impact. By setting up tests in controlled environments—like telling an AI it will be shut down—you can discover and mitigate dangerous emergent behaviors before release.

In regulated industries like finance, the primary barrier to full AI automation is often regulation, not just user trust. It is the technology provider's responsibility to prove AI's reliability and safety to regulators, much like the industry did to legitimize e-signatures over a decade ago.

In high-stakes industries like finance and healthcare, the ability to deploy autonomous AI is directly tied to the ability to prove it operates within safe, predefined boundaries. Rather than slowing innovation, robust governance is the prerequisite for safely activating autonomous systems in regulated environments.

A16z argues we are in the "Wright Brothers moment" of AI. Regulating foundational models now—which are essentially just math—would stifle fundamental discovery, akin to trying to regulate flight experiments before airplanes existed. The focus should be on application-level harms, not the underlying technology development.

AI expert Max Tegmark argues that regulation, like the FDA for pharma, would shift incentives. Instead of a 'race to the bottom' on unchecked capabilities, companies would compete to be first to develop provably safe AI. This would create a golden age of innovation in areas like medicine while sidelining riskier applications.

An FDA-style regulatory model would force AI companies to make a quantitative safety case for their models before deployment. This shifts the burden of proof from regulators to creators, creating powerful financial incentives for labs to invest heavily in safety research, much like pharmaceutical companies invest in clinical trials.

The popular idea of a government 'sign-off' before an AI model's release is based on a false premise. Risk isn't a one-time event at launch; it's continuous, existing during model development, internal use, and post-release updates. Effective oversight must reflect this ongoing reality.